SNCAIP siRNA (Human) | MyBioSource MBS8222926 product information

product summary

company name :

MyBioSource

product type :

gene knockdown

product name :

SNCAIP siRNA (Human)

catalog :

MBS8222926

quantity :

15 nmol

price :

365 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS8222926

products type :

siRNA

products full name :

SNCAIP siRNA (Human)

products short name :

[SNCAIP]

products name syn :

[Synphilin-1; Sph1; Alpha-synuclein-interacting protein]

other names :

[synphilin-1 isoform 1A; Synphilin-1; synphilin-1; synuclein, alpha interacting protein; Alpha-synuclein-interacting protein]

products gene name :

[SNCAIP]

other gene names :

[SNCAIP; SNCAIP; Sph1; SYPH1; Sph1]

uniprot entry name :

SNCAP_HUMAN

host :

Synthetic

reactivity :

Human

sequence length :

603

specificity :

SNCAIP siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

purity :

> 97%

form :

Lyophilized powder

storage stability :

Shipping: Blue ice. Store at -20°C for one year.

tested application :

RNA Interference (RNAi)

other info2 :

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency. Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well). Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SNCAIP gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.

products description :

siRNA to inhibit SNCAIP expression using RNA interference

ncbi gi num :

339409220

ncbi acc num :

NP_001229864.1

ncbi gb acc num :

NM_001242935.2

uniprot acc num :

Q9Y6H5

ncbi pathways :

Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

ncbi summary :

This gene encodes a protein containing several protein-protein interaction domains, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding motif. The encoded protein interacts with alpha-synuclein in neuronal tissue and may play a role in the formation of cytoplasmic inclusions and neurodegeneration. A mutation in this gene has been associated with Parkinson's disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]

uniprot summary :

SNCAIP: Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1. Defects in SNCAIP may be a cause of Parkinson disease (PARK). A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. 6 isoforms of the human protein are produced by alternative splicing. Protein type: Vesicle. Chromosomal Location of Human Ortholog: 5q23.2. Cellular Component: presynaptic membrane; synaptic vesicle; cell soma; cytoplasm. Molecular Function: identical protein binding; protein binding; ubiquitin protein ligase binding. Biological Process: regulation of neurotransmitter secretion; dopamine metabolic process. Disease: Parkinson Disease, Late-onset

size1 :

15 nmol

price1 :

365 USD

size2 :

30 nmol

price2 :

515

more info or order :

MyBioSource product webpage